Aspen Neuroscience is set to raise capital via an initial public offering, while Bambusa also plans an IPO, extending momentum for new public-market listings in cell therapy and biotech-adjacent platforms. The reporting frames Aspen as a Parkinson’s-focused cell therapy company targeting disease modification rather than symptomatic relief. The IPO comes as investors continue to weigh early clinical differentiation and platform credibility for advanced therapeutics. For Aspen, the key near-term focus will be translating preclinical and clinical signals into investor confidence while building manufacturing readiness appropriate for cell therapies. For the sector, concurrent IPO plans reinforce that capital markets remain receptive to pipeline-driven stories—particularly those tied to neurologic unmet need and potentially disruptive modalities. Deal timing and follow-on financing dynamics may affect how quickly such companies can expand trials and de-risk manufacturing constraints.